Clinical trials: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well low-intensity chemotherapy and blinatumomab work in treating patients with Philadelphia chromosome negative acute lymphoblastic leukemia that has come back or does not respond to treatment.
- Conditions
- Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Trial name
- NCT03518112
- Testing
- Blinatumomab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive…
- Trial name
- NCT00884286
- Testing
- Aplidin®
- Where
- 12 sites in France, Italy and 4 more
- Volunteers
- 67 people
- Sponsor
- PharmaMar
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for…
- Trial name
- NCT02077166
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- 40 sites in United States, Belgium and 2 more
- Volunteers
- 138 people
- Sponsor
- Pharmacyclics LLC.
B-Cell Lymphoma
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
This study will examine the safety and effectiveness of an experimental drug called Bortezomib (PS-341), given alone and in combination with a chemotherapy regimen called Etoposide, Prednisone, Vincristine, Cyclophosphamide…
- Trial name
- NCT00054665
- Testing
- PS-341, Etoposide, Doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT01261247
- Testing
- panobinostat, laboratory biomarker analysis, western blotting
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Mayo Clinic
Diffuse Large B Cell Lymphoma
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT01481129
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 9 sites in France
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
This phase II trial studies how well pembrolizumab alone or with idelalisib or ibrutinib works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas that have returned after a…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT02332980
- Testing
- Ibrutinib, Idelalisib, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Non-Hodgkin's Lymphoma
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
This is a open-label, multicenter, non-randomized, study to evaluate the safety, efficacy, and pharmacokinetics of idasanutlin in combination with obinutuzumab in participants with R/R FL and rituximab in combination with…
- Trial name
- NCT02624986
- Testing
- Idasanutlin, Obinutuzumab, Rituximab
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT01075321
- Testing
- everolimus, lenalidomide, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Mayo Clinic
Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of selinexor when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or aggressive non-Hodgkin lymphoma that has returned after a period…
- Conditions
- Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT02303392
- Testing
- Selinexor, Ibrutinib, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Jennifer Woyach
Non-Hodgkin Lymphoma
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of…
- Trial name
- BELINDA (NCT03570892)
- Testing
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin Lymphoma
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
This is an open-label, multicenter study to characterize the safety and efficacy of the human anti-CD19 antibody MOR00208 in adult patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) who have received at least 1 prior…
- Trial name
- NCT01685008
- Testing
- MOR00208 (formerly Xmab 5574)
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 92 people
- Sponsor
- MorphoSys AG